32 results about "Locally advanced" patented technology

The invention provides methods and compositions for classifying kidney cancer (e.g., RCC, e.g., an inoperable, locally advanced, or metastatic RCC); methods and compositions for treating kidney cancer in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab) to the patient. Also provided are compositions, pharmaceutical compositions, kits, and articles of manufacture for use in classifying and treating kidney cancer in a patient.

The invention relates to the technical field of rectal cancer, and discloses an AI-based local advanced rectal cancer neoadjuvant therapy curative effect prediction system, which comprises a data collection and processing module, a prediction model construction and training module, a prediction model verification and optimization module and a clinical application module, the data collecting and processing module is used for collecting clinical data, image data, radiotherapy target area data, radiotherapy dose data, radiobiology data and genomics data of a patient and then transmitting the data to the prediction model building and training module, and the prediction model building and training module extracts and selects key features in the data. And constructing a tumor segmentation multi-modal fusion and calibration network prediction model based on the PET / CT image. According to the invention, the data of the patient is collected through the data collection and processing module, so that the accuracy of radiotherapy effect and side reaction prediction is improved through the constructed prediction model, and the problem of feature capture limitation caused by a single center and a single mode of an existing AI model is solved.

The invention discloses an application of a reagent for detecting AP3S2 in preparation of a diagnostic reagent for neoadjuvant immunochemotherapy resistance of gastric cancer in a local progression stage, which comprises the following steps: screening differential expression proteins in neoadjuvant immunochemotherapy resistance tissues of gastric cancer in the local progression stage through proteomics; a new marker is provided for diagnosis of the local progression stage gastric cancer immunochemotherapy drug resistance, and a basis is also provided for development and future development of a local progression stage gastric cancer immunochemotherapy drug resistance diagnosis method.

The present disclosure provides, inter alia, methods of treating locally advanced, recurrent or metastatic solid tumor malignancies in a subject by administering an anti-CCR8 antibody to the subject in need thereof, and related therapeutic uses.

To provide a method for treating patients having HER2-positive metastatic or locally advanced breast cancer in first-line therapy.SOLUTION: A method comprising administering a therapeutically effective amount of an anti-HER2 maytansinoid conjugate to a patient having breast cancer who has received prior treatment with a taxane.SELECTED DRAWING: None

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

This invention provides a combination therapy comprising a PI3K inhibitor (e.g., epfuliximab), a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant; and a method for treating patients (preferably those with PIC3CA mutations) with hormone receptor-positive and HER2-negative (HR+ / HER2-) locally advanced or metastatic breast cancer, the method comprising administering a therapeutically effective amount of epfuliximab or a pharmaceutically acceptable salt thereof, a CDK4 / 6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.

To provide methods and compounds for use in treating and / or preventing breast cancer, including locally advanced or metastatic, ER+, HER2- breast cancer, in a subject in need of treatment.SOLUTION: Treating and / or preventing methods are provided which comprise administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof.SELECTED DRAWING: Figure 8

To provide pharmaceutical formulations and administration regimens for treating cancer comprising a multi-specific binding protein that binds to HER2, NKG2D and CD16.SOLUTION: The disclosure relates to pharmaceutical formulations for multispecific binding proteins having an scFv that binds to epidermal growth factor receptor 2 (ErbB2 or HER2), a Fab that binds to NKG2D, and an antibody Fc domain. Dosage regimens for such multispecific binding proteins and pharmaceutical formulations for the treatment of cancer, such as locally advanced or metastatic solid tumors, are also provided. The disclosure provides pharmaceutical formulations comprising multispecific binding proteins comprising a HER2-binding scFv, a Fab that binds to NKG2D and an antibody Fc domain, of which ingredients are optimized for the stability of the multispecific protein.SELECTED DRAWING: None

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The application discloses application of a CDK4 / 6 inhibitor combined with oxaliplatin in preparation of a treatment drug for chemotherapy-resistant colorectal cancer. The combined use of the CDK4 / 6 inhibitor combined with oxaliplatin has excellent therapeutic effect on locally advanced rectal cancer which is resistant to a first-line chemotherapy scheme, can overcome the drug resistance of the rectal cancer patient to the chemotherapy drug, so that the tumor proliferation is inhibited, and the apoptosis of the cancer cell is promoted. The application provides a combined drug treatment scheme for neoadjuvant therapy of locally advanced rectal cancer chemotherapy resistance, can achieve the purpose of effectively treating or assisting in treating the rectal cancer, and provides a new way for treating, diagnosing or predicting the rectal cancer patient.

The present invention relates generally to methods of treating HER2-positive locally advanced or previously untreated metastatic breast cancer, and particularly provides methods of treating HER2-positive, locally advanced or previously untreated metastatic breast cancer with an anti-HER2-maytansine conjugate (e.g., trastuzumab-eimetanin) that has received prior treatment with a taxane, a method of treating a patient with locally advanced or previously untreated metastatic breast cancer.

The present invention provides methods for treating and / or preventing breast cancer, including locally advanced or metastatic ER+ and HER2- breast cancers in patients requiring treatment, compounds for use in treatment, and combinations thereof. [Solution] Administer a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotope derivative thereof, or a prodrug thereof. JPEG2026136114000154.jpg65134

The present disclosure relates to using ivonescimab, an anti-VEGF x anti-PD-1 bispecific antibody, optionally in combination with other therapies, to treat cancers. Disclosed embodiments include: ivonescimab or ivonescimab in combination with ligufalimab to treat head and neck squamous cell carcinoma (e.g., PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma); perioperative ivonescimab or ivonescimab in combination with chemotherapy to treat resectable non-small cell lung cancer; ivonescimab in combination with chemotherapy or in combination with ligufalimab and chemotherapy to treat colorectal cancer (e.g., recurrent or metastatic colorectal cancer); ivonescimab to treat advanced non-small cell lung cancer; and ivonescimab in combination with chemotherapy to treat locally advanced unresectable or metastatic triple-negative breast cancer.

The present invention provides methods and compositions for treating bladder cancer (e.g., urothelial carcinoma (UC), including locally advanced or metastatic UC) in a subject, for example, by administering to the patient a treatment regimen that includes a PD-1 axis binding antagonist (e.g., acterizumab). The present invention also provides compositions (e.g., PD-1 axis binding antagonists (e.g., atrizumab) and / or platinum based chemotherapies (e.g., cis-platinum or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in the treatment of bladder cancer (e.g., UC, including locally advanced or metastatic UC) in a patient. The invention also provides assays and methods for determining the presence and / or expression level of PD-L1 in a sample obtained from a patient and for labeling PD-L1 in a sample obtained from a patient.

The present disclosure provides a protein marker, detection reagent or detection tool for early identification of local regional advanced nasopharyngeal carcinoma induction chemotherapy responders. Since PON1 protein, IGFBP3 protein, v‑kappa‑3 protein and DDX55 protein are significantly differentially expressed in the plasma of healthy individuals and untreated local regional advanced nasopharyngeal carcinoma patients, the plasma of induction chemotherapy responders and ineffective patients before treatment, the plasma of induction chemotherapy responders before and after treatment, and the plasma samples of induction chemotherapy responders and ineffective patients after treatment, PON1 protein, IGFBP3 protein, v‑kappa‑3 protein and DDX55 protein can be used to identify potential responders of induction chemotherapy for local regional advanced nasopharyngeal carcinoma before treatment, showing excellent test benefits. The method is simple and easy to implement, easy for patients to accept, has unified execution standards and follows objective data, and can further optimize the clinical application of induction chemotherapy for local regional advanced nasopharyngeal carcinoma, especially innovative treatment in key areas such as oncology.

The present disclosure provides, inter alia, methods of treating a locally advanced, recurrent, or metastatic solid tumor malignancy in a subject in need thereof by administering an anti-CCR8 antibody to the subject, and related therapeutic uses.

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

The invention discloses application of a reagent for detecting DHCR24 in preparation of a reagent for diagnosing neoadjuvant immunochemotherapy resistance of gastric cancer in a local progression stage, differentially expressed proteins in neoadjuvant immunochemotherapy resistance tissues of the gastric cancer in the local progression stage are screened out through proteomics, and a new marker is provided for diagnosis of the neoadjuvant immunochemotherapy resistance of the gastric cancer in the local progression stage. And a foundation is provided for the development and future development of a diagnosis method for the immunochemotherapy drug resistance of the gastric cancer in the local development stage.

The invention discloses application of a reagent for detecting PLS1 in preparation of a reagent for diagnosing neoadjuvant immunochemotherapy resistance of gastric cancer in a local progression stage, differentially expressed proteins in neoadjuvant immunochemotherapy resistance tissues of gastric cancer in the local progression stage are screened out through proteomics, and a new marker is provided for diagnosis of neoadjuvant immunochemotherapy resistance of gastric cancer in the local progression stage. And a foundation is provided for the development and future development of a diagnosis method for the immunochemotherapy drug resistance of the gastric cancer in the local development stage.

The invention provides methods and compositions for treating bladder cancer (e.g., urothelial carcinoma (UC), including locally advanced or metastatic UC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab) and / or a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating bladder cancer (e.g., UC, including locally advanced or metastatic UC) in a patient. Also provided are assays and methods for determining the presence and / or expression level of PD-L1 in a sample obtained from a patient and for labeling PD-L1 in a sample obtained from a patient.

The invention discloses application of a biomarker in diagnosis / prediction of peritoneal relapse after a local progression stage gastric cancer operation, and particularly relates to a biomarker which is BUB1, CKS2, PCNA, CHEK1, NEK2, NCAPG2 or a combination of the BUB1, the CKS2, the PCNA, the CHEK1, the NEK2 and the NCAPG2. Through the systematic and comprehensive biomarker discovery and multi-sample verification method, a six-genome and risk stratification model is determined to detect the risk of peritoneal relapse after a high-risk gastric cancer operation, and if the risk is discovered as early as possible, information decision can be provided for clinic, and the treatment result of a patient can be improved.

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

This invention discloses a method and system for constructing an intelligent quality control platform for radiotherapy based on multimodal data, belonging to the field of intelligent quality control technology for radiotherapy. The method includes: collaborating with at least two cross-regional medical centers to collect multimodal data from patients with locally advanced rectal cancer; performing multi-expert annotation on the target area and organs at risk on the CT images according to unified annotation standards; generating consensus annotations using a multi-annotation fusion algorithm; and forming a multi-center standardized dataset after standardization processing. It also involves the parallel construction of an automatic segmentation model, an automatic quality control module for radiotherapy planning, and a multimodal risk stratification model; integrating the automatic segmentation model, automatic quality control module, and risk stratification model into a Web-based platform; and interacting with the radiotherapy information system and radiotherapy planning system through an interface adaptation layer. This provides precise support for promoting the homogenization of radiotherapy quality and the implementation of precision radiotherapy.

The descriptive memorandum refers to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of previously EGFR TKI-naïve patients with metastatic or locally advanced EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with platinum-based chemotherapy and pemetrexed.

The invention relates to the technical field of medicines, in particular to application of isomaltotetraose and an anti-cancer medicine composition. The isomaltotetraose can be used as a YWHAB inhibitor combined with an anti-metabolic anti-tumor drug and a cytotoxic anti-tumor drug, for example, the combination of FOLFOX chemotherapy and isomaltotetraose has an excellent treatment effect on YWHAB high expression type local development stage colorectal cancer. The medicines are combined to overcome the drug resistance caused by anti-metabolic anti-tumor medicines and cytotoxic anti-tumor medicines, so that the effects of inhibiting the proliferation of tumor cells and promoting the apoptosis of cancer cells are achieved.

A combination therapy comprising enoxacin, palbociclib, and fulvestrant is provided, along with a method for treating locally advanced or metastatic breast cancer with PIC3CA mutations, hormone receptor-positive (HR+), and HER2-negative (HER2-), the method comprising administering therapeutically effective amounts of enoxacin, palbociclib, and fulvestrant. The combination therapy produced statistically significant and clinically meaningful improvements in comparable patients compared to administration of palbociclib and fulvestrant alone.

The present invention provides methods and compositions for treating cancer (e.g., locally advanced, recurrent or metastatic solid tumors) in a subject, for example by administering to the subject an anti-cancer therapy comprising an anti-latent TGF-beta1 antibody. Also provided are compositions (e.g., anti-latent TGF-beta 1 antibodies, pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in the treatment of cancer in a subject.